Market Intelligence on Zinc Finger Transcription Factor Degraders for Multiple Myeloma and Lymphoid Malignancies. Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IKZF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IKZF1 Recombinant Protein (Zinc Finger Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Human/Mouse orthologs available. |
View IKZF1 Products |
| Mutant Panel | IKZF1 Cys2His2 Zinc Finger Mutants Key mutations (Q146H, V/IXX) abolishing CRBN binding or DNA recognition for selectivity assays. Also includes CVID13 mutations (e.g., rs7, rs8) that disrupt DNA binding. |
View IKZF1 Products |
| Gene Delivery | IKZF1 Lentivirus Premade Particles Full-length ORF for stable cell line construction in hematopoietic cells. |
View IKZF1 Products |
| Benchmark Ab | Anti-IKZF1 Reference Antibody Recombinant positive control for western blot and degradation assays. |
View IKZF1 Products |
| Validator | IKZF1 siRNA Set (3 unique sequences) For knockdown verification in degradation assays. |
View IKZF1 Products |
| Related Target: IKZF3 | IKZF3 (Aiolos) Protein & Gene Paralog zinc finger protein; critical for selectivity screening (IKZF1-sparing vs dual degraders). |
View IKZF3 Products |
| Related Target: CRBN | Cereblon (CRBN) Recombinant Protein E3 ligase substrate receptor; required for ternary complex formation assays. |
View CRBN Products |
| Related Target: IRF4 | IRF4 Protein & Antibody Downstream transcription factor regulated by IKZF1; biomarker for efficacy. |
View IRF4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation (IKZF1-CRBN-Ligand) | Sequence-Verified IKZF1 & CRBN proteins with >95% purity; suitable for SPR/Biacore and ITC binding studies. |
| Selectivity vs Paralog IKZF3 | Strictly verified IKZF1 and IKZF3 zinc finger domains with distinct epitope tags for multiplexed detection. |
| Drug-Resistance Mutation Screening | Pre-made IKZF1 zinc finger mutants (Q146H, etc.) for validation of resistance mechanisms. |
| Cell-Based Degradation Assay | High-titer IKZF1 Lentivirus (>10^8 TU/ml) for stable overexpression in MM1.S or KMS-11 cell lines. |
| Degradation Controls & Phenotypic Validation | High-affinity reference antibodies for precise Western Blot/HiBiT readouts; validated siRNA set for specificity checks and target validation in cell-based assays. |
Live IKZF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IKZF1-targeted therapeutics is intensifying, with major players shifting from pan-IMiD approaches to selective IKZF1 degraders. As first-generation CELMoDs (Cereblon E3 Ligase Modulators) face limitations due to simultaneous IKZF3 degradation (causing neutropenia), the next wave of R&D targets IKZF1-selective molecular glues and PROTACs to improve the therapeutic index in multiple myeloma and non-Hodgkin lymphoma. Key players like BMS, C4 Therapeutics (CFT7455), Monte Rosa, and Kymera are actively developing next-generation degraders that can overcome IMiD resistance and precisely tune degradation profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue (CELMoD) | BMS, C4 Therapeutics | Relapsed/Refractory Multiple Myeloma | Ternary Complex Formation (Need purified IKZF1 + CRBN) |
| PROTAC Degrader | Nurix, Kymera, Arvinas | Non-Hodgkin Lymphoma, Hematological Malignancies | Ubiquitination Assay (Need WT vs Mutant IKZF1 proteins) |
| Selective IKZF1 Degrader | C4 Therapeutics (CFT7455) | Peripheral T-cell Lymphoma | Selectivity Panel (IKZF1 vs IKZF3 Zinc Finger Domains) |
| Transcriptional Inhibitor | Early Discovery | Acute Lymphoblastic Leukemia | DNA-Binding EMSA (Need high-activity Zinc Finger protein) |
| Small Molecule Inhibitor (Preclinical) | Preclinical Biotech | Solid Tumors (Emerging) | Selectivity Assay (Need Homolog panels and off-target screening) |
Related Targets for Cross-Sell
Beyond the above, supplement your workflow with SALL4 for off-target toxicity screening (teratogenicity risk), and anti-IKZF1/IKZF3 antibodies for biomarker detection.